S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News

$6.62
-0.20 (-2.93%)
(As of 06/7/2023 ET)
Compare
Today's Range
$6.62
$7.02
50-Day Range
$4.52
$9.09
52-Week Range
$3.68
$9.65
Volume
552,500 shs
Average Volume
4.01 million shs
Market Capitalization
$627.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

ARS Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.4% Upside
$13.67 Price Target
Short Interest
Bearish
7.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.07mentions of ARS Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$724,600 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.75) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

623rd out of 981 stocks

Pharmaceutical Preparations Industry

306th out of 485 stocks


SPRY stock logo

About ARS Pharmaceuticals (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPRY Stock News Headlines

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.8%
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Wedbush Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
ARS Pharmaceuticals Inc.
Why ARS Pharmaceuticals Stock Is Soaring Today
See More Headlines

SPRY Price History

SPRY Company Calendar

Last Earnings
5/15/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRY
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.67
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+106.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-34,680,000.00
Pretax Margin
-6,299.11%

Debt

Sales & Book Value

Annual Sales
$1.32 million
Book Value
$2.90 per share

Miscellaneous

Free Float
62,172,000
Market Cap
$627.38 million
Optionable
Optionable
Beta
-0.17

Key Executives

  • Mr. Richard Lowenthal M.B.A. (Age 56)
    M.S., MSMSEL, Founder, Pres, CEO & Director
  • Dr. Sarina Tanimoto M.B.A. (Age 54)
    M.D., Co-Founder & Chief Medical Officer
  • Dr. Robert Bell Ph.D.
    Co-Founder & Chief Science Officer
  • Ms. Kathleen D. Scott CPA
    Chief Financial Officer
  • Mr. Brian T. Dorsey M.S.
    SVP of Operations & Project Management
  • Mr. Daniel Relovsky
    Sr. VP of Marketing
  • Mr. Harris Kaplan M.B.A. (Age 70)
    MBA, Exec. VP of Commercial Strategy
  • Mr. Eric Karas (Age 50)
    Chief Commercial Officer
  • Mr. Justin Chakma (Age 33)
    Chief Bus. Officer & Sec.













SPRY Stock - Frequently Asked Questions

Should I buy or sell ARS Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRY shares.
View SPRY analyst ratings
or view top-rated stocks.

What is ARS Pharmaceuticals' stock price forecast for 2023?

3 brokerages have issued 12-month price targets for ARS Pharmaceuticals' stock. Their SPRY share price forecasts range from $10.00 to $17.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price.
View analysts price targets for SPRY
or view top-rated stocks among Wall Street analysts.

How have SPRY shares performed in 2023?

ARS Pharmaceuticals' stock was trading at $8.53 at the beginning of 2023. Since then, SPRY stock has decreased by 22.4% and is now trading at $6.62.
View the best growth stocks for 2023 here
.

When is ARS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SPRY earnings forecast
.

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.02 million for the quarter.

What is ARS Pharmaceuticals' stock symbol?

ARS Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPRY."

Who are ARS Pharmaceuticals' major shareholders?

ARS Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include SR One Capital Management LP (4.23%), Baker BROS. Advisors LP (2.12%), Geode Capital Management LLC (0.43%), Royce & Associates LP (0.32%), Ameriprise Financial Inc. (0.30%) and Jane Street Group LLC (0.15%). Insiders that own company stock include Kathleen D Scott and Laura Shawver.
View institutional ownership trends
.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARS Pharmaceuticals' stock price today?

One share of SPRY stock can currently be purchased for approximately $6.62.

How much money does ARS Pharmaceuticals make?

ARS Pharmaceuticals (NASDAQ:SPRY) has a market capitalization of $627.38 million and generates $1.32 million in revenue each year.

How can I contact ARS Pharmaceuticals?

ARS Pharmaceuticals' mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The official website for the company is ars-pharma.com. The company can be reached via phone at 206-456-2900 or via email at ir@silverbacktx.com.

This page (NASDAQ:SPRY) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -